{"_default": {}, "triggers": {"1": {"rule_id": "balance_critical", "rule_name": "Solde critique", "priority": 1, "timestamp": "2026-01-21T19:49:21.949766", "context": {"recent_changes": [], "monitor_decision": {"should_trigger": false, "reason": "no_changes"}, "last_run_date": null, "current_balance": 0, "cash_runway_days": 180}, "saved_at": "2026-01-21T19:49:21.949853"}, "2": {"rule_id": "new_critical_invoice", "rule_name": "Facture critique d\u00e9tect\u00e9e", "priority": 1, "timestamp": "2026-01-21T19:50:58.558127", "context": {"recent_changes": [{"severity": "critical", "type": "new_row", "details": {"invoice_id": "F-DEMO-20260121-195031", "client_id": "CLI-LABORATOIR", "client_name": "Laboratoires BioPharm SAS", "invoice_date": "2025-08-12", "due_date": "2025-08-27", "amount": 850000.0, "status": "overdue", "payment_date": null, "days_overdue": 120, "risk_level": "critical"}}], "monitor_decision": {"should_trigger": true, "reason": "critical_change_detected (1 changes)"}, "last_run_date": "2026-01-21T19:49:58.551802", "current_balance": 4545500, "cash_runway_days": 165}, "saved_at": "2026-01-21T19:50:58.558785"}}, "runs": {"1": {"run_id": "4ec28841-3f49-4aca-9ab8-f1a0290c744e", "timestamp": "2026-01-21T19:49:58.551802", "trigger_reason": "Solde critique", "deliverables": {"treasury": {"current_balance": 4545500, "as_of_date": "2026-01-21", "total_inflows_mtd": 2515000, "total_outflows_mtd": 575500, "pending_client_payments": 8250000, "pending_supplier_payments": 278000, "cash_runway_days": 165, "status": "safe"}, "forecasts": {"4_weeks": {"horizon_weeks": 4, "horizon_label": "Court terme (4 sem.)", "start_balance": 4545500, "projected_inflows": 2867550.0, "projected_outflows": 0.0, "end_balance": 7413050.0, "min_balance": 4545500, "min_balance_date": "2026-01-21", "probability_weighted_balance": 7413050.0, "status": "safe", "weekly_breakdown": [{"week": 1, "start_date": "2026-01-21", "end_date": "2026-01-28", "inflows": 957550.0, "outflows": 0.0, "net_flow": 957550.0, "end_balance": 5503050.0}, {"week": 2, "start_date": "2026-01-28", "end_date": "2026-02-04", "inflows": 510750.0, "outflows": 0.0, "net_flow": 510750.0, "end_balance": 6013800.0}, {"week": 3, "start_date": "2026-02-04", "end_date": "2026-02-11", "inflows": 631500.0, "outflows": 0.0, "net_flow": 631500.0, "end_balance": 6645300.0}, {"week": 4, "start_date": "2026-02-11", "end_date": "2026-02-18", "inflows": 767750.0, "outflows": 0.0, "net_flow": 767750.0, "end_balance": 7413050.0}]}, "8_weeks": {"horizon_weeks": 8, "horizon_label": "Moyen terme (8 sem.)", "start_balance": 4545500, "projected_inflows": 3361800.0, "projected_outflows": 0.0, "end_balance": 7907300.0, "min_balance": 4545500, "min_balance_date": "2026-01-21", "probability_weighted_balance": 7907300.0, "status": "safe", "weekly_breakdown": [{"week": 1, "start_date": "2026-01-21", "end_date": "2026-01-28", "inflows": 957550.0, "outflows": 0.0, "net_flow": 957550.0, "end_balance": 5503050.0}, {"week": 2, "start_date": "2026-01-28", "end_date": "2026-02-04", "inflows": 510750.0, "outflows": 0.0, "net_flow": 510750.0, "end_balance": 6013800.0}, {"week": 3, "start_date": "2026-02-04", "end_date": "2026-02-11", "inflows": 631500.0, "outflows": 0.0, "net_flow": 631500.0, "end_balance": 6645300.0}, {"week": 4, "start_date": "2026-02-11", "end_date": "2026-02-18", "inflows": 767750.0, "outflows": 0.0, "net_flow": 767750.0, "end_balance": 7413050.0}, {"week": 5, "start_date": "2026-02-18", "end_date": "2026-02-25", "inflows": 122500.0, "outflows": 0.0, "net_flow": 122500.0, "end_balance": 7535550.0}, {"week": 6, "start_date": "2026-02-25", "end_date": "2026-03-04", "inflows": 177750.0, "outflows": 0.0, "net_flow": 177750.0, "end_balance": 7713300.0}, {"week": 7, "start_date": "2026-03-04", "end_date": "2026-03-11", "inflows": 0.0, "outflows": 0.0, "net_flow": 0.0, "end_balance": 7713300.0}, {"week": 8, "start_date": "2026-03-11", "end_date": "2026-03-18", "inflows": 194000.0, "outflows": 0.0, "net_flow": 194000.0, "end_balance": 7907300.0}]}, "13_weeks": {"horizon_weeks": 13, "horizon_label": "Long terme (13 sem.)", "start_balance": 4545500, "projected_inflows": 3534800.0, "projected_outflows": 0.0, "end_balance": 8080300.0, "min_balance": 4545500, "min_balance_date": "2026-01-21", "probability_weighted_balance": 8080300.0, "status": "safe", "weekly_breakdown": [{"week": 1, "start_date": "2026-01-21", "end_date": "2026-01-28", "inflows": 957550.0, "outflows": 0.0, "net_flow": 957550.0, "end_balance": 5503050.0}, {"week": 2, "start_date": "2026-01-28", "end_date": "2026-02-04", "inflows": 510750.0, "outflows": 0.0, "net_flow": 510750.0, "end_balance": 6013800.0}, {"week": 3, "start_date": "2026-02-04", "end_date": "2026-02-11", "inflows": 631500.0, "outflows": 0.0, "net_flow": 631500.0, "end_balance": 6645300.0}, {"week": 4, "start_date": "2026-02-11", "end_date": "2026-02-18", "inflows": 767750.0, "outflows": 0.0, "net_flow": 767750.0, "end_balance": 7413050.0}, {"week": 5, "start_date": "2026-02-18", "end_date": "2026-02-25", "inflows": 122500.0, "outflows": 0.0, "net_flow": 122500.0, "end_balance": 7535550.0}, {"week": 6, "start_date": "2026-02-25", "end_date": "2026-03-04", "inflows": 177750.0, "outflows": 0.0, "net_flow": 177750.0, "end_balance": 7713300.0}, {"week": 7, "start_date": "2026-03-04", "end_date": "2026-03-11", "inflows": 0.0, "outflows": 0.0, "net_flow": 0.0, "end_balance": 7713300.0}, {"week": 8, "start_date": "2026-03-11", "end_date": "2026-03-18", "inflows": 194000.0, "outflows": 0.0, "net_flow": 194000.0, "end_balance": 7907300.0}, {"week": 9, "start_date": "2026-03-18", "end_date": "2026-03-25", "inflows": 0.0, "outflows": 0.0, "net_flow": 0.0, "end_balance": 7907300.0}, {"week": 10, "start_date": "2026-03-25", "end_date": "2026-04-01", "inflows": 119000.0, "outflows": 0.0, "net_flow": 119000.0, "end_balance": 8026300.0}, {"week": 11, "start_date": "2026-04-01", "end_date": "2026-04-08", "inflows": 0.0, "outflows": 0.0, "net_flow": 0.0, "end_balance": 8026300.0}, {"week": 12, "start_date": "2026-04-08", "end_date": "2026-04-15", "inflows": 0.0, "outflows": 0.0, "net_flow": 0.0, "end_balance": 8026300.0}, {"week": 13, "start_date": "2026-04-15", "end_date": "2026-04-22", "inflows": 54000.0, "outflows": 0.0, "net_flow": 54000.0, "end_balance": 8080300.0}]}}, "risks": [{"id": "RISK-005", "category": "client_payment", "severity": "critical", "score": 93, "title": "Retard paiement Groupe Pharmaceutique Nord", "description": "Facture F-2025-061 en retard de 93 jours", "amount_at_risk": 525000, "due_date": "2025-10-20", "entity_id": "CLI-009", "entity_name": "Groupe Pharmaceutique Nord", "days_overdue": 93, "recommended_action": "Relancer Groupe Pharmaceutique Nord - priorit\u00e9 imm\u00e9diate"}, {"id": "RISK-007", "category": "client_payment", "severity": "high", "score": 86, "title": "Retard paiement Institut Recherche Appliqu\u00e9e", "description": "Facture F-2025-078 en retard de 81 jours", "amount_at_risk": 640000, "due_date": "2025-11-01", "entity_id": "CLI-013", "entity_name": "Institut Recherche Appliqu\u00e9e", "days_overdue": 81, "recommended_action": "Relancer Institut Recherche Appliqu\u00e9e - priorit\u00e9 haute"}, {"id": "RISK-002", "category": "client_payment", "severity": "high", "score": 80, "title": "Retard paiement Groupe Innov Sant\u00e9", "description": "Facture F-2026-003 en retard de 68 jours", "amount_at_risk": 615000, "due_date": "2025-11-14", "entity_id": "CLI-003", "entity_name": "Groupe Innov Sant\u00e9", "days_overdue": 68, "recommended_action": "Relancer Groupe Innov Sant\u00e9 - priorit\u00e9 haute"}, {"id": "RISK-012", "category": "supplier", "severity": "high", "score": 75, "title": "Facture fournisseur impay\u00e9e - Cabinet Audit & Contr\u00f4le", "description": "Facture SUPP-2026-002 en retard de 32 jours", "amount_at_risk": 45000, "due_date": "2025-12-20", "entity_id": "SUPP-002", "entity_name": "Cabinet Audit & Contr\u00f4le", "days_overdue": 32, "recommended_action": "R\u00e9gulariser le paiement de Cabinet Audit & Contr\u00f4le"}, {"id": "RISK-008", "category": "client_payment", "severity": "high", "score": 72, "title": "Retard paiement PME Innovation Sant\u00e9", "description": "Facture F-2025-085 en retard de 51 jours", "amount_at_risk": 380000, "due_date": "2025-12-01", "entity_id": "CLI-016", "entity_name": "PME Innovation Sant\u00e9", "days_overdue": 51, "recommended_action": "Relancer PME Innovation Sant\u00e9 - priorit\u00e9 haute"}, {"id": "RISK-009", "category": "client_payment", "severity": "medium", "score": 68, "title": "Retard paiement Groupe Export International", "description": "Facture F-2025-092 en retard de 42 jours", "amount_at_risk": 560000, "due_date": "2025-12-10", "entity_id": "CLI-019", "entity_name": "Groupe Export International", "days_overdue": 42, "recommended_action": "Relancer Groupe Export International - priorit\u00e9 haute"}, {"id": "RISK-004", "category": "client_payment", "severity": "medium", "score": 64, "title": "Retard paiement Startup DeepTech IA", "description": "Facture F-2026-007 en retard de 37 jours", "amount_at_risk": 165000, "due_date": "2025-12-15", "entity_id": "CLI-007", "entity_name": "Startup DeepTech IA", "days_overdue": 37, "recommended_action": "Relancer Startup DeepTech IA - priorit\u00e9 haute"}, {"id": "RISK-011", "category": "client_payment", "severity": "medium", "score": 62, "title": "Retard paiement Groupe Industrie 4.0", "description": "Facture F-2025-105 en retard de 34 jours", "amount_at_risk": 490000, "due_date": "2025-12-18", "entity_id": "CLI-024", "entity_name": "Groupe Industrie 4.0", "days_overdue": 34, "recommended_action": "Relancer Groupe Industrie 4.0 - priorit\u00e9 haute"}, {"id": "RISK-001", "category": "client_payment", "severity": "medium", "score": 61, "title": "Retard paiement Laboratoires BioPharm SAS", "description": "Facture F-2026-001 en retard de 32 jours", "amount_at_risk": 485000, "due_date": "2025-12-20", "entity_id": "CLI-001", "entity_name": "Laboratoires BioPharm SAS", "days_overdue": 32, "recommended_action": "Relancer Laboratoires BioPharm SAS - priorit\u00e9 haute"}, {"id": "RISK-010", "category": "client_payment", "severity": "medium", "score": 58, "title": "Retard paiement ETI Manufacturing", "description": "Facture F-2025-098 en retard de 27 jours", "amount_at_risk": 315000, "due_date": "2025-12-25", "entity_id": "CLI-021", "entity_name": "ETI Manufacturing", "days_overdue": 27, "recommended_action": "Relancer ETI Manufacturing - priorit\u00e9 haute"}, {"id": "RISK-003", "category": "client_payment", "severity": "medium", "score": 56, "title": "Retard paiement Conseil Strat\u00e9gie & Finance", "description": "Facture F-2026-006 en retard de 24 jours", "amount_at_risk": 125000, "due_date": "2025-12-28", "entity_id": "CLI-006", "entity_name": "Conseil Strat\u00e9gie & Finance", "days_overdue": 24, "recommended_action": "Relancer Conseil Strat\u00e9gie & Finance - priorit\u00e9 haute"}, {"id": "RISK-006", "category": "client_payment", "severity": "medium", "score": 54, "title": "Retard paiement FinTech Solutions Europe", "description": "Facture F-2025-050 en retard de 21 jours", "amount_at_risk": 195000, "due_date": "2025-12-31", "entity_id": "CLI-010", "entity_name": "FinTech Solutions Europe", "days_overdue": 21, "recommended_action": "Relancer FinTech Solutions Europe - priorit\u00e9 haute"}], "actions": [{"id": "ACTION-001", "priority": 1, "category": "recouvrement", "action": "Appeler Groupe Pharmaceutique Nord pour obtenir un engagement de paiement sous 48h", "expected_impact": 525000, "deadline": "2026-01-23", "effort": "low", "risk_ids": ["RISK-005"]}, {"id": "ACTION-002", "priority": 2, "category": "recouvrement", "action": "Campagne de relance pour 3 factures en retard", "expected_impact": 981000.0, "deadline": "2026-02-04", "effort": "medium", "risk_ids": ["RISK-007", "RISK-002", "RISK-008"]}, {"id": "ACTION-003", "priority": 3, "category": "fournisseurs", "action": "R\u00e9gulariser 1 factures fournisseurs en retard", "expected_impact": 45000, "deadline": "2026-01-28", "effort": "low", "risk_ids": ["RISK-012"]}], "dg_note": "# Note Direction Financi\u00e8re\n**Date:** Aujourd'hui  \n**Objet:** Point de situation tr\u00e9sorerie et risques associ\u00e9s\n\n## Situation actuelle\n\nLa position de tr\u00e9sorerie de Demo PME-ETI pr\u00e9sente un solde de 4,545,500\u20ac, offrant une visibilit\u00e9 de 165 jours d'exploitation. Les encours sont caract\u00e9ris\u00e9s par :\n- Un montant clients significatif de 8,250,000\u20ac\n- Des dettes fournisseurs ma\u00eetris\u00e9es \u00e0 278,000\u20ac\n\n## Points de vigilance\n\nLa cartographie des risques met en \u00e9vidence :\n- 1 risque critique et 4 risques \u00e9lev\u00e9s\n- Un montant total expos\u00e9 de 4,540,000\u20ac, soit quasi-\u00e9quivalent \u00e0 notre tr\u00e9sorerie actuelle\n- Une cr\u00e9ance sensible de 525,000\u20ac sur le Groupe Pharmaceutique Nord, actuellement en retard de paiement\n\nLe ratio encours clients/fournisseurs r\u00e9v\u00e8le un d\u00e9s\u00e9quilibre important dans notre BFR, avec des cr\u00e9ances clients repr\u00e9sentant pr\u00e8s de 30 fois le montant des dettes fournisseurs.\n\n## Recommandations\n\nActions imm\u00e9diates \u00e0 mettre en \u0153uvre :\n1. **Priorit\u00e9 absolue** : Mobilisation urgente aupr\u00e8s du Groupe Pharmaceutique Nord\n   - Objectif : Obtenir un engagement ferme de paiement sous 48h\n   - Escalade au niveau Direction G\u00e9n\u00e9rale si n\u00e9cessaire\n\n2. **Actions de recouvrement** :\n   - Lancement d'une campagne de relance cibl\u00e9e sur les 3 factures identifi\u00e9es comme critiques\n   - Mise en place d'un suivi quotidien des encaissements attendus\n\n3. **Pilotage renforc\u00e9** :\n   - Reporting quotidien sur l'\u00e9volution des encours clients\n   - Point hebdomadaire sur l'avancement des actions de recouvrement\n\nLa situation reste sous contr\u00f4le mais n\u00e9cessite une vigilance accrue et une action rapide sur les cr\u00e9ances en retard pour s\u00e9curiser notre position de tr\u00e9sorerie.", "risk_explanations": {"RISK-005": "Le retard de paiement de 525k\u20ac du Groupe Pharmaceutique Nord est particuli\u00e8rement critique car il d\u00e9passe le d\u00e9lai usuel de 90 jours, exposant l'entreprise \u00e0 un risque de cr\u00e9ance douteuse. Bien que la tr\u00e9sorerie actuelle soit confortable (4.5M\u20ac), ce montant repr\u00e9sente la totalit\u00e9 de notre seuil critique de s\u00e9curit\u00e9 (500k\u20ac), ce qui pourrait compromettre notre capacit\u00e9 \u00e0 faire face \u00e0 d'autres impr\u00e9vus. Une action de recouvrement imm\u00e9diate est n\u00e9cessaire, avec escalade possible au niveau juridique."}, "action_justification": "La priorisation propos\u00e9e est logique pour les raisons suivantes :\n\nP1 - Groupe Pharmaceutique Nord (525k\u20ac) : Priorit\u00e9 maximale car c'est une action rapide (appel unique) avec un fort impact financier imm\u00e9diat. L'obtention d'un engagement \u00e9crit sous 48h s\u00e9curise la tr\u00e9sorerie \u00e0 tr\u00e8s court terme.\n\nP2 - Campagne de relance (981k\u20ac) : Bien que l'impact soit plus \u00e9lev\u00e9, cette action n\u00e9cessite plus de temps et de ressources pour traiter 3 factures distinctes. Elle est plac\u00e9e en P2 car le retour sur investissement est plus dilu\u00e9 dans le temps.\n\nP3 - R\u00e9gularisation fournisseur (45k\u20ac) : Impact financier plus faible et moins urgent en comparaison. La r\u00e9gularisation peut \u00eatre trait\u00e9e apr\u00e8s la s\u00e9curisation des entr\u00e9es de tr\u00e9sorerie plus significatives.\n\nCette priorisation optimise le ratio impact/effort en privil\u00e9giant d'abord les actions \u00e0 fort impact et ex\u00e9cution rapide."}, "summary": {"balance": 4545500, "runway_days": 165, "risks_count": 12, "actions_count": 3}}, "2": {"run_id": "ca4cce7b-4c69-4e96-9010-ccecdb099271", "timestamp": "2026-01-21T19:51:40.786518", "trigger_reason": "Facture critique d\u00e9tect\u00e9e", "deliverables": {"treasury": {"current_balance": 4545500, "as_of_date": "2026-01-21", "total_inflows_mtd": 2515000, "total_outflows_mtd": 575500, "pending_client_payments": 9100000.0, "pending_supplier_payments": 278000, "cash_runway_days": 165, "status": "safe"}, "forecasts": {"4_weeks": {"horizon_weeks": 4, "horizon_label": "Court terme (4 sem.)", "start_balance": 4545500, "projected_inflows": 2867550.0, "projected_outflows": 0.0, "end_balance": 7413050.0, "min_balance": 4545500, "min_balance_date": "2026-01-21", "probability_weighted_balance": 7413050.0, "status": "safe", "weekly_breakdown": [{"week": 1, "start_date": "2026-01-21", "end_date": "2026-01-28", "inflows": 957550.0, "outflows": 0.0, "net_flow": 957550.0, "end_balance": 5503050.0}, {"week": 2, "start_date": "2026-01-28", "end_date": "2026-02-04", "inflows": 510750.0, "outflows": 0.0, "net_flow": 510750.0, "end_balance": 6013800.0}, {"week": 3, "start_date": "2026-02-04", "end_date": "2026-02-11", "inflows": 631500.0, "outflows": 0.0, "net_flow": 631500.0, "end_balance": 6645300.0}, {"week": 4, "start_date": "2026-02-11", "end_date": "2026-02-18", "inflows": 767750.0, "outflows": 0.0, "net_flow": 767750.0, "end_balance": 7413050.0}]}, "8_weeks": {"horizon_weeks": 8, "horizon_label": "Moyen terme (8 sem.)", "start_balance": 4545500, "projected_inflows": 3361800.0, "projected_outflows": 0.0, "end_balance": 7907300.0, "min_balance": 4545500, "min_balance_date": "2026-01-21", "probability_weighted_balance": 7907300.0, "status": "safe", "weekly_breakdown": [{"week": 1, "start_date": "2026-01-21", "end_date": "2026-01-28", "inflows": 957550.0, "outflows": 0.0, "net_flow": 957550.0, "end_balance": 5503050.0}, {"week": 2, "start_date": "2026-01-28", "end_date": "2026-02-04", "inflows": 510750.0, "outflows": 0.0, "net_flow": 510750.0, "end_balance": 6013800.0}, {"week": 3, "start_date": "2026-02-04", "end_date": "2026-02-11", "inflows": 631500.0, "outflows": 0.0, "net_flow": 631500.0, "end_balance": 6645300.0}, {"week": 4, "start_date": "2026-02-11", "end_date": "2026-02-18", "inflows": 767750.0, "outflows": 0.0, "net_flow": 767750.0, "end_balance": 7413050.0}, {"week": 5, "start_date": "2026-02-18", "end_date": "2026-02-25", "inflows": 122500.0, "outflows": 0.0, "net_flow": 122500.0, "end_balance": 7535550.0}, {"week": 6, "start_date": "2026-02-25", "end_date": "2026-03-04", "inflows": 177750.0, "outflows": 0.0, "net_flow": 177750.0, "end_balance": 7713300.0}, {"week": 7, "start_date": "2026-03-04", "end_date": "2026-03-11", "inflows": 0.0, "outflows": 0.0, "net_flow": 0.0, "end_balance": 7713300.0}, {"week": 8, "start_date": "2026-03-11", "end_date": "2026-03-18", "inflows": 194000.0, "outflows": 0.0, "net_flow": 194000.0, "end_balance": 7907300.0}]}, "13_weeks": {"horizon_weeks": 13, "horizon_label": "Long terme (13 sem.)", "start_balance": 4545500, "projected_inflows": 3534800.0, "projected_outflows": 0.0, "end_balance": 8080300.0, "min_balance": 4545500, "min_balance_date": "2026-01-21", "probability_weighted_balance": 8080300.0, "status": "safe", "weekly_breakdown": [{"week": 1, "start_date": "2026-01-21", "end_date": "2026-01-28", "inflows": 957550.0, "outflows": 0.0, "net_flow": 957550.0, "end_balance": 5503050.0}, {"week": 2, "start_date": "2026-01-28", "end_date": "2026-02-04", "inflows": 510750.0, "outflows": 0.0, "net_flow": 510750.0, "end_balance": 6013800.0}, {"week": 3, "start_date": "2026-02-04", "end_date": "2026-02-11", "inflows": 631500.0, "outflows": 0.0, "net_flow": 631500.0, "end_balance": 6645300.0}, {"week": 4, "start_date": "2026-02-11", "end_date": "2026-02-18", "inflows": 767750.0, "outflows": 0.0, "net_flow": 767750.0, "end_balance": 7413050.0}, {"week": 5, "start_date": "2026-02-18", "end_date": "2026-02-25", "inflows": 122500.0, "outflows": 0.0, "net_flow": 122500.0, "end_balance": 7535550.0}, {"week": 6, "start_date": "2026-02-25", "end_date": "2026-03-04", "inflows": 177750.0, "outflows": 0.0, "net_flow": 177750.0, "end_balance": 7713300.0}, {"week": 7, "start_date": "2026-03-04", "end_date": "2026-03-11", "inflows": 0.0, "outflows": 0.0, "net_flow": 0.0, "end_balance": 7713300.0}, {"week": 8, "start_date": "2026-03-11", "end_date": "2026-03-18", "inflows": 194000.0, "outflows": 0.0, "net_flow": 194000.0, "end_balance": 7907300.0}, {"week": 9, "start_date": "2026-03-18", "end_date": "2026-03-25", "inflows": 0.0, "outflows": 0.0, "net_flow": 0.0, "end_balance": 7907300.0}, {"week": 10, "start_date": "2026-03-25", "end_date": "2026-04-01", "inflows": 119000.0, "outflows": 0.0, "net_flow": 119000.0, "end_balance": 8026300.0}, {"week": 11, "start_date": "2026-04-01", "end_date": "2026-04-08", "inflows": 0.0, "outflows": 0.0, "net_flow": 0.0, "end_balance": 8026300.0}, {"week": 12, "start_date": "2026-04-08", "end_date": "2026-04-15", "inflows": 0.0, "outflows": 0.0, "net_flow": 0.0, "end_balance": 8026300.0}, {"week": 13, "start_date": "2026-04-15", "end_date": "2026-04-22", "inflows": 54000.0, "outflows": 0.0, "net_flow": 54000.0, "end_balance": 8080300.0}]}}, "risks": [{"id": "RISK-012", "category": "client_payment", "severity": "critical", "score": 100, "title": "Retard paiement Laboratoires BioPharm SAS", "description": "Facture F-DEMO-20260121-195031 en retard de 147 jours", "amount_at_risk": 850000.0, "due_date": "2025-08-27", "entity_id": "CLI-LABORATOIR", "entity_name": "Laboratoires BioPharm SAS", "days_overdue": 147, "recommended_action": "Relancer Laboratoires BioPharm SAS - priorit\u00e9 imm\u00e9diate"}, {"id": "RISK-005", "category": "client_payment", "severity": "critical", "score": 93, "title": "Retard paiement Groupe Pharmaceutique Nord", "description": "Facture F-2025-061 en retard de 93 jours", "amount_at_risk": 525000.0, "due_date": "2025-10-20", "entity_id": "CLI-009", "entity_name": "Groupe Pharmaceutique Nord", "days_overdue": 93, "recommended_action": "Relancer Groupe Pharmaceutique Nord - priorit\u00e9 imm\u00e9diate"}, {"id": "RISK-007", "category": "client_payment", "severity": "high", "score": 86, "title": "Retard paiement Institut Recherche Appliqu\u00e9e", "description": "Facture F-2025-078 en retard de 81 jours", "amount_at_risk": 640000.0, "due_date": "2025-11-01", "entity_id": "CLI-013", "entity_name": "Institut Recherche Appliqu\u00e9e", "days_overdue": 81, "recommended_action": "Relancer Institut Recherche Appliqu\u00e9e - priorit\u00e9 haute"}, {"id": "RISK-002", "category": "client_payment", "severity": "high", "score": 80, "title": "Retard paiement Groupe Innov Sant\u00e9", "description": "Facture F-2026-003 en retard de 68 jours", "amount_at_risk": 615000.0, "due_date": "2025-11-14", "entity_id": "CLI-003", "entity_name": "Groupe Innov Sant\u00e9", "days_overdue": 68, "recommended_action": "Relancer Groupe Innov Sant\u00e9 - priorit\u00e9 haute"}, {"id": "RISK-013", "category": "supplier", "severity": "high", "score": 75, "title": "Facture fournisseur impay\u00e9e - Cabinet Audit & Contr\u00f4le", "description": "Facture SUPP-2026-002 en retard de 32 jours", "amount_at_risk": 45000, "due_date": "2025-12-20", "entity_id": "SUPP-002", "entity_name": "Cabinet Audit & Contr\u00f4le", "days_overdue": 32, "recommended_action": "R\u00e9gulariser le paiement de Cabinet Audit & Contr\u00f4le"}, {"id": "RISK-008", "category": "client_payment", "severity": "high", "score": 72, "title": "Retard paiement PME Innovation Sant\u00e9", "description": "Facture F-2025-085 en retard de 51 jours", "amount_at_risk": 380000.0, "due_date": "2025-12-01", "entity_id": "CLI-016", "entity_name": "PME Innovation Sant\u00e9", "days_overdue": 51, "recommended_action": "Relancer PME Innovation Sant\u00e9 - priorit\u00e9 haute"}, {"id": "RISK-009", "category": "client_payment", "severity": "medium", "score": 68, "title": "Retard paiement Groupe Export International", "description": "Facture F-2025-092 en retard de 42 jours", "amount_at_risk": 560000.0, "due_date": "2025-12-10", "entity_id": "CLI-019", "entity_name": "Groupe Export International", "days_overdue": 42, "recommended_action": "Relancer Groupe Export International - priorit\u00e9 haute"}, {"id": "RISK-004", "category": "client_payment", "severity": "medium", "score": 64, "title": "Retard paiement Startup DeepTech IA", "description": "Facture F-2026-007 en retard de 37 jours", "amount_at_risk": 165000.0, "due_date": "2025-12-15", "entity_id": "CLI-007", "entity_name": "Startup DeepTech IA", "days_overdue": 37, "recommended_action": "Relancer Startup DeepTech IA - priorit\u00e9 haute"}, {"id": "RISK-011", "category": "client_payment", "severity": "medium", "score": 62, "title": "Retard paiement Groupe Industrie 4.0", "description": "Facture F-2025-105 en retard de 34 jours", "amount_at_risk": 490000.0, "due_date": "2025-12-18", "entity_id": "CLI-024", "entity_name": "Groupe Industrie 4.0", "days_overdue": 34, "recommended_action": "Relancer Groupe Industrie 4.0 - priorit\u00e9 haute"}, {"id": "RISK-001", "category": "client_payment", "severity": "medium", "score": 61, "title": "Retard paiement Laboratoires BioPharm SAS", "description": "Facture F-2026-001 en retard de 32 jours", "amount_at_risk": 485000.0, "due_date": "2025-12-20", "entity_id": "CLI-001", "entity_name": "Laboratoires BioPharm SAS", "days_overdue": 32, "recommended_action": "Relancer Laboratoires BioPharm SAS - priorit\u00e9 haute"}, {"id": "RISK-010", "category": "client_payment", "severity": "medium", "score": 58, "title": "Retard paiement ETI Manufacturing", "description": "Facture F-2025-098 en retard de 27 jours", "amount_at_risk": 315000.0, "due_date": "2025-12-25", "entity_id": "CLI-021", "entity_name": "ETI Manufacturing", "days_overdue": 27, "recommended_action": "Relancer ETI Manufacturing - priorit\u00e9 haute"}, {"id": "RISK-003", "category": "client_payment", "severity": "medium", "score": 56, "title": "Retard paiement Conseil Strat\u00e9gie & Finance", "description": "Facture F-2026-006 en retard de 24 jours", "amount_at_risk": 125000.0, "due_date": "2025-12-28", "entity_id": "CLI-006", "entity_name": "Conseil Strat\u00e9gie & Finance", "days_overdue": 24, "recommended_action": "Relancer Conseil Strat\u00e9gie & Finance - priorit\u00e9 haute"}, {"id": "RISK-006", "category": "client_payment", "severity": "medium", "score": 54, "title": "Retard paiement FinTech Solutions Europe", "description": "Facture F-2025-050 en retard de 21 jours", "amount_at_risk": 195000.0, "due_date": "2025-12-31", "entity_id": "CLI-010", "entity_name": "FinTech Solutions Europe", "days_overdue": 21, "recommended_action": "Relancer FinTech Solutions Europe - priorit\u00e9 haute"}], "actions": [{"id": "ACTION-001", "priority": 1, "category": "recouvrement", "action": "Appeler Laboratoires BioPharm SAS pour obtenir un engagement de paiement sous 48h", "expected_impact": 850000.0, "deadline": "2026-01-23", "effort": "low", "risk_ids": ["RISK-012"]}, {"id": "ACTION-002", "priority": 1, "category": "recouvrement", "action": "Appeler Groupe Pharmaceutique Nord pour obtenir un engagement de paiement sous 48h", "expected_impact": 525000.0, "deadline": "2026-01-23", "effort": "low", "risk_ids": ["RISK-005"]}, {"id": "ACTION-003", "priority": 2, "category": "recouvrement", "action": "Campagne de relance pour 3 factures en retard", "expected_impact": 981000.0, "deadline": "2026-02-04", "effort": "medium", "risk_ids": ["RISK-007", "RISK-002", "RISK-008"]}, {"id": "ACTION-004", "priority": 3, "category": "fournisseurs", "action": "R\u00e9gulariser 1 factures fournisseurs en retard", "expected_impact": 45000, "deadline": "2026-01-28", "effort": "low", "risk_ids": ["RISK-013"]}], "dg_note": "# Note DAF - Situation Tr\u00e9sorerie et Risques\n*Date: [Date du jour]*\n\n## Situation actuelle\n\nLa position de tr\u00e9sorerie de Demo PME-ETI pr\u00e9sente un solde positif de 4,5M\u20ac, offrant une visibilit\u00e9 de 165 jours d'exploitation. Le niveau d'encours clients s'\u00e9l\u00e8ve \u00e0 9,1M\u20ac, contrastant avec un encours fournisseurs ma\u00eetris\u00e9 de 278K\u20ac.\n\nLa situation est actuellement consid\u00e9r\u00e9e comme s\u00e9curis\u00e9e (\"safe\"), mais n\u00e9cessite une vigilance particuli\u00e8re compte tenu des risques identifi\u00e9s.\n\n## Points de vigilance\n\n- Un montant total de 5,39M\u20ac est actuellement consid\u00e9r\u00e9 \u00e0 risque, repr\u00e9sentant plus que le solde de tr\u00e9sorerie disponible\n- 2 risques critiques ont \u00e9t\u00e9 identifi\u00e9s, concernant des retards de paiement majeurs :\n  * Laboratoires BioPharm SAS : 850K\u20ac\n  * Groupe Pharmaceutique Nord : 525K\u20ac\n- 4 autres risques class\u00e9s comme \"\u00e9lev\u00e9s\" sont \u00e9galement sous surveillance\n\n## Recommandations\n\nActions imm\u00e9diates \u00e0 mettre en \u0153uvre :\n\n1. **Actions prioritaires clients strat\u00e9giques**\n   * Contacter en urgence Laboratoires BioPharm SAS pour s\u00e9curiser un engagement de paiement sous 48h\n   * M\u00eame d\u00e9marche aupr\u00e8s du Groupe Pharmaceutique Nord\n\n2. **Actions de recouvrement**\n   * Lancer une campagne de relance cibl\u00e9e sur les 3 factures actuellement en retard\n   * Renforcer le suivi des autres risques \u00e9lev\u00e9s identifi\u00e9s\n\n3. **Pilotage**\n   * Mettre en place un reporting quotidien sur l'avancement des actions de recouvrement\n   * Pr\u00e9voir un point de situation hebdomadaire avec la Direction G\u00e9n\u00e9rale jusqu'\u00e0 r\u00e9sorption des risques critiques\n\nLa situation reste sous contr\u00f4le mais n\u00e9cessite une action rapide et coordonn\u00e9e pour s\u00e9curiser les encaissements prioritaires.", "risk_explanations": {"RISK-012": "Le retard de paiement critique de BioPharm SAS (850k\u20ac) repr\u00e9sente pr\u00e8s de 19% de notre tr\u00e9sorerie actuelle, avec un d\u00e9lai anormalement \u00e9lev\u00e9 de 147 jours. Bien que notre position de tr\u00e9sorerie soit actuellement confortable, ce retard chronique pourrait signaler des difficult\u00e9s financi\u00e8res chez ce client majeur. Une action de recouvrement imm\u00e9diate est n\u00e9cessaire, avec potentiellement une r\u00e9\u00e9valuation des conditions de paiement futures avec ce client.", "RISK-005": "Le retard de paiement de 525K\u20ac du Groupe Pharmaceutique Nord est critique car il d\u00e9passe largement le d\u00e9lai standard de paiement (93 jours) et repr\u00e9sente plus de 11% de notre tr\u00e9sorerie actuelle. Bien que notre position de tr\u00e9sorerie soit actuellement confortable, le montant impay\u00e9 \u00e9quivaut \u00e0 la totalit\u00e9 de notre seuil critique de tr\u00e9sorerie (500K\u20ac), ce qui pourrait rapidement devenir probl\u00e9matique en cas d'autres retards clients. Une action de recouvrement imm\u00e9diate est n\u00e9cessaire, possiblement via notre service contentieux."}, "action_justification": "La priorisation est justifi\u00e9e ainsi :\n\nP1 - Les appels \u00e0 BioPharm (850k\u20ac) et Groupe Pharma Nord (525k\u20ac) sont prioritaires car ils repr\u00e9sentent des montants significatifs avec un fort potentiel de recouvrement rapide sous 48h. L'action directe par t\u00e9l\u00e9phone permet une r\u00e9ponse imm\u00e9diate et un engagement ferme de paiement.\n\nP2 - La campagne de relance (981k\u20ac) arrive en second car, bien que le montant soit plus \u00e9lev\u00e9, elle concerne plusieurs factures et clients diff\u00e9rents, avec un d\u00e9lai de traitement plus long et un taux de succ\u00e8s moins imm\u00e9diat que les appels directs P1.\n\nP3 - La r\u00e9gularisation fournisseur (45k\u20ac) est en derni\u00e8re position car son montant est relativement faible et n'impacte pas directement la tr\u00e9sorerie entrante, contrairement aux autres actions qui g\u00e9n\u00e8rent des encaissements.\n\nCette priorisation optimise l'impact sur la tr\u00e9sorerie \u00e0 court terme tout en tenant compte des d\u00e9lais de traitement et de la probabilit\u00e9 de succ\u00e8s de chaque action."}, "summary": {"balance": 4545500, "runway_days": 165, "risks_count": 13, "actions_count": 4}}}}